Navigation Links
EntreMed to Present at BioPartnering Europe Conference
Date:10/10/2008

ny developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation -- processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

Forward Looking Statements

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance (including the timing of royalty revenues and future R&D expenditures), strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under "Risk Factors," including risks relating to the need for additional capital and the uncertainty of additional funding; variations in actual sales of Thalomid(R), risks associated with the Company's product candidates; the early-stage products under development; results in preclinical models a
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
2. EntreMed Reports Second Quarter 2008 Financial Results
3. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
4. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
5. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
6. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
7. EntreMed Receives Nasdaq Deficiency Notice
8. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
9. EntreMed Announces 2008 Corporate and Clinical Program Priorities
10. EntreMed Reports Fourth Quarter and Year-End 2007 Financial Results
11. EntreMed to Present at BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Eckert & Ziegler Vitalea Science (EZVS), ... to the pharmaceutical and biotech industry, has announced that ... the position of Director of Science & Technology. , ... experience in drug metabolism and bioanalysis to EZVS in ...
(Date:1/22/2015)... BOSTON , Jan. 22, 2015  Transwestern | RBJ today ... feet of office space for Shire a leading biopharmaceutical company, ... . Transwestern | RBJ,s Robert Richards , president, and ... the lease for the entire five-floor building at 95 Hayden ...
(Date:1/22/2015)... Jan. 22, 2015  Transwestern | RBJ today announces the firm ... space for Shire a leading biopharmaceutical company, at Two Ledgemont ... RBJ,s Robert Richards , president, and Brian Cohen ... the entire five-floor building at 95 Hayden Ave. ...
(Date:1/22/2015)... The laboratory information management systems market is a rapidly ... advancements due to factors such as rising pressure to ... systems, and increasing government support for adoption of HCIT ... in the market focus on technological advancements to further ...
Breaking Biology Technology:Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 2Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 3Laboratory Information Management Systems Market is Expected to Reach $1,323.6 Million by 2019 - New Research Report by MarketsandMarkets 4
... Agencourt offers sequencing services designed specifically for clients who , ... has many features that allow us to provide industry-leading sequence ... Comprehensive genomic , pipeline ... , Patented SPRI technology , ...
... Kevin McKernan, Jim Yang, Betty Woolf, Rey Sequerra, Kathy Makowski, Tom , ... Corporation, Beverly, MA 01915, USA, Abstract , ... response , and disease susceptibility is becoming, ... Since the completion of the Human, ...
... The Isopure Buccal Cell DNA Kit is a simple, streamlined method ... for downstream applications , such as PCR. The ... collection formats using SPRI magnetic bead technology , ... Buccal Kit effectively and consistently delivers high purity and ...
Cached Biology Technology:cDNA Sequencing & Finishing 2SeeSNP Propietary Analysis Advantages 2SeeSNP Propietary Analysis Advantages 3SeeSNP Propietary Analysis Advantages 4SeeSNP Propietary Analysis Advantages 5SeeSNP Propietary Analysis Advantages 6Isopure - Buccal cell DNA isolation 2
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 Research and ... the addition of the "The Global Watermarking ... http://photos.prnewswire.com/prnh/20130307/600769 ... global digital media watermarking and fingerprinting markets. Watermarking ...
(Date:12/19/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/86ncd6/micro_market ) has ... America Perimeter Security Systems Market" report to their offering. ... North American perimeter security market is estimated to grow at ... U.S. market holds a larger share in this market, ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2The Global Watermarking and Fingerprinting Markets 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 2Micro Market Monitor: North America Perimeter Security Systems Market (Intrusion Detection Sensor, Video Surveillance, Communication/Alarm and Notification, Access Control System) 3
... Super-small particles of silicon react with water to produce ... In a series of experiments, the scientists created ... combined with water, these particles reacted to form silicic ... source of energy for fuel cells. The reaction ...
... in the Jan. 17 issue of The Journal of ... assistant professor of biochemistry and molecular biology at Saint Louis ... breast cancer, an often deadly and treatment resistant form of ... and her team identified vitamin D and some protease inhibitors ...
... paper published in Nature Communications on January 22, ... of the Natural History Museum of Los Angeles County,s (NHM) ... of an avian dinosaur species. Confuciusornis sanctus ... some had long, almost body length ornamental tail feathers, ...
Cached Biology News:Just add water: How scientists are using silicon to produce hydrogen on demand 2Vitamin D holds promise in battling a deadly breast cancer, Saint Louis University researchers say 2Vitamin D holds promise in battling a deadly breast cancer, Saint Louis University researchers say 3Vitamin D holds promise in battling a deadly breast cancer, Saint Louis University researchers say 4Sex of early birds suggests dinosaur reproductive style 2
Rabbit polyclonal to MA2 ( Abpromise for all tested applications). entrezGeneID: 10687 SwissProtID: Q9UL42...
... FANCM ( Abpromise for all tested ... peptide derived from within residues 2000 to ... the amino acid sequence is proprietary) ... .) Entrez GeneID: ...
Mouse monoclonal [YPF19] to Yersinia pestis ( Abpromise for all tested applications)....
Rabbit polyclonal to 13,14 dihydro 15 keto Prostaglandin E2 ( Abpromise for all tested applications)....
Biology Products: